[Residual risk in cardiovascular prevention].
Despite meaningful progress in the identification of risk factors and the development of highly effective prevention tools, the residual risk of cardiovascular events remains high (about 60-70% in the major outcome trials dealing with statins). Awareness of this problem can properly orient the search for new effective and efficient preventive strategies.
Rapezzi
Claudio
C
Istituto di Cardiologia, Università degli Studi, Policlinico S. Orsola-Malpighi, Bologna. claudio.rapezzi@unibo.it
Volpe
Massimo
M
D050197:Atherosclerosis / Q000517:prevention & control; D001794:Blood Pressure; D001835:Body Weight; D063387:Cannabinoid Receptor Antagonists; D002186:Cannabinoids / Q000037:antagonists & inhibitors; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D010880:Piperidines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000077285:Rimonabant; D012307:Risk Factors; D016540:Smoking Cessation; D053778:Thiazolidines / Q000627:therapeutic use; D013997:Time Factors
D063387:Cannabinoid Receptor Antagonists; D002186:Cannabinoids; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D010880:Piperidines; D011720:Pyrazoles; D053778:Thiazolidines; D000077285:Rimonabant